SCHEMBL3937009

SCHEMBL3937009

CCC(=O)NS(=O)(=O)c1ccc(NC(=O)COc2ccc(Br)c(Oc3cc(Cl)cc(C#N)c3)c2F)c(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 2/20 0.39
KCNH2 Q12809 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
MAPT P10636 1/20 0.36
CA1 P00915 3/20 0.35
CA2 P00918 3/20 0.35
CA12 O43570 2/20 0.35
CA4 P22748 2/20 0.35
MAOB P27338 2/20 0.35
CA5A P35218 2/20 0.35
CA7 P43166 2/20 0.35
CA5B Q9Y2D0 2/20 0.35
SLC2A1 P11166 2/20 0.35
RAB9A P51151 2/20 0.35
NPC1 O15118 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ALDH1A1 P00352 2/20 0.34
VEGFA P15692 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3945972 0.94 SLC2A1 (0.40) SLC22A12KCNH2SMN1; SMN2CYP2C19MAPT
SCHEMBL3938422 0.90 CA1 (0.45) SLC22A12KCNH2CA1CA2CA12
Elsulfavirine SCHEMBL1341521 0.88 CA1 (0.40) SLC22A12CYP2C19CA1CA2CA12
Elsulfavirine SCHEMBL1344216 0.88 CA1 (0.40) SLC22A12CYP2C19CA1CA2CA12
Elsulfavirine SCHEMBL1344214 0.88 CA1 (0.39) SLC22A12CYP2C19CA1CA2CA12
SCHEMBL4140860 0.86 CA1 (0.47) CA1CA2CA12CA4MAOB
SCHEMBL3940886 0.84 CA1 (0.48) CA1CA2CA12CA4MAOB
SCHEMBL3945671 0.84 SLC2A1 (0.42) SLC22A12KCNH2MAPTCA1CA2
SCHEMBL3945113 0.84 CA1 (0.43) SMN1; SMN2CYP1A2CYP2C19CA1CA2
SCHEMBL3944827 0.83 CA1 (0.46) SLC22A12CA1CA2CA12CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2046731-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS F. Hoffmann-Roche AG (CH) 2009-04-15 EP claimed
WO-2008009613-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2008-01-24 WO claimed
US-20080020981-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2008-01-24 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080020981-A1 Non-nucleoside reverse transcriptase inhibitors SAMHD1, HPRT1, NQO2 SLC22A12 2351/4885KCNH2 4114/4885SMN1; SMN2 3307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.